The market for complement inhibitors is expected to grow significantly in the coming years. Since the launch of SOLIRIS and ULTOMIRIS, the complement inhibitor market has seen a lot of traction, and many companies are now developing novel complement inhibitors, potentially paralleling the efficacy and safety profile of eculizumab. LAS VEGAS , Aug.
21, 2024 /PRNewswire/ -- DelveInsight's Complement Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging complement inhibitors, market share of individual therapies, and current and forecasted complement inhibitors market size from 2020 to 2034, segmented into 7MM [ the United States , the EU-4 ( Italy , Spain , France , and Germany ), the United Kingdom , and Japan ]. Key Takeaways from the Complement Inhibitors Market Report As per DelveInsight's analysis, the current market size of complement inhibitors is estimated to be approximately USD 7 billion , in the 7MM in 2023. Leading complement inhibitors companies such as Genentech, Ionis, Roche, AKARI Therapeutics, CARE Pharma, NovelMed Therapeutics, Omeros Corporation, and others are developing novel complement inhibitors that can be available in the complement inhibitors market in the coming years.
Some of the key complement inhibitors include Crovalimab, IONIS-FB-LRx/RG6299, Nomacopan, CAN-106, Ruxoprubart, OMS-906 , and others. In February 2024 , the FDA granted an Orphan Drug Designation (ODD) to ruxoprubart for the tr.